Neurofilament Light Chain (NfL): A Pivotal Biomarker for Neurological Injury and ANT BIO PTE. LTD.'s Solutions

1. Concept: Neurofilament Light Chain (NfL)

Neurofilament Light Chain (NfL, also known as NFL or NEFL) is the smallest and most abundant subunit of neuronal neurofilaments (NFs)—the major cytoskeletal components of neurons. Neurofilaments consist of four core subunits: NfL, neurofilament medium chain (NFM), neurofilament heavy chain (NFH), and α-internexin or peripherin. These subunits assemble into 10 nm filaments, with their concentrations varying by neuron type, axonal location, and developmental stage.

Human NfL has a molecular weight of approximately 68 kDa, featuring a conserved rod domain (Coil 1a, Coil 1b, Coil 2a/b) and terminal regions. As a foundational cytoskeletal protein, NfL plays critical roles in maintaining axonal structural integrity, ensuring efficient neuronal signal transmission, and regulating axonal diameter. It undergoes post-translational modifications (e.g., phosphorylation, glycosylation) that modulate neurofilament assembly and function. Under physiological conditions, NfL release is minimal—with cerebrospinal fluid (CSF) levels <1800 pg/ml and blood levels <10 pg/ml (restricted by the blood-brain barrier). However, axonal injury or neurodegeneration triggers significant NfL release, elevating its levels in CSF and blood, making it a sensitive biomarker for neurological disorders.

2. Research Frontiers of NfL in Neuroscience

Contemporary research on NfL focuses on expanding its clinical utility and technical detection capabilities. A key frontier is the validation of NfL as a universal biomarker for differential diagnosis of neurodegenerative diseases (e.g., Alzheimer’s disease vs. Parkinson’s disease) and acute neurological injuries (e.g., stroke, traumatic brain injury). Another prominent direction involves exploring NfL’s role in predicting disease progression and treatment response in conditions like multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). Additionally, advancements in ultra-sensitive detection technologies—such as single-molecule array (SiMoA) and digital ELISA—are enhancing the accuracy of blood NfL quantification, enabling non-invasive monitoring of neurological health. Furthermore, research is investigating multi-biomarker panels (e.g., NfL + GFAP + Tau) to improve the specificity of dementia risk stratification and early diagnosis.

3. Research Significance of NfL

Neurological disorders affect over 3 billion people globally, ranking as the leading cause of morbidity and disability. The global market for neurodegenerative disease treatments is projected to grow from USD 14.66 billion (2021) to USD 22.79 billion (2029) at a CAGR of 5.67%. NfL research addresses critical unmet needs in neuroscience:

• Non-invasive diagnosis: Blood NfL quantification eliminates the need for invasive CSF sampling, improving patient accessibility to neurological screening.
• Early detection: Elevated NfL levels precede clinical symptoms in many neurodegenerative diseases, enabling early intervention.
• Disease monitoring: NfL levels correlate with axonal damage severity, facilitating real-time assessment of disease progression and treatment efficacy.
• Risk stratification: Combined with other biomarkers (e.g., GFAP), NfL enhances the prediction of dementia risk and mortality.
• Translational value: NfL accelerates clinical trials by providing objective endpoints for evaluating neuroprotective therapies.

4. Relevant Mechanisms, Research Methods and Product Applications

4.1 Core Mechanisms of NfL in Neurological Disorders

In healthy neurons, NfL stabilizes the axonal cytoskeleton and supports signal propagation. In pathological conditions (e.g., neurodegeneration, axonal trauma, inflammation), neuronal damage disrupts the cytoskeleton, leading to NfL release into the extracellular space. NfL then enters CSF and, to a lesser extent, the bloodstream (via blood-brain barrier leakage). Elevated NfL levels are observed in:

• Neurodegenerative diseases: Alzheimer’s disease (AD), Parkinson’s disease (PD), ALS, frontotemporal dementia (FTD).
• Inflammatory disorders: Multiple sclerosis (MS), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
• Acute injuries: Stroke, traumatic brain injury (TBI), seizures.

Blood and CSF NfL levels exhibit a strong positive correlation (R = 0.7–0.8), validating blood-based testing as a non-invasive alternative to CSF analysis.

4.2 Key Research Methods for NfL Detection

• Single-Molecule Array (SiMoA): Offers picogram-level sensitivity, enabling accurate quantification of low-abundance NfL in blood. It uses fluorescent magnetic beads coated with capture antibodies, with signal detection in single-microwell chips.
• ELISA/Electrochemiluminescence (ECL): Traditional methods for NfL detection in CSF and blood, with sandwich ELISA formats providing high specificity.
• Western Blot: Qualitative and semi-quantitative analysis of NfL in tissue or cell lysates, supporting mechanistic research.
• Immunohistochemistry (IHC): Visualization of NfL localization in brain tissues, aiding in the study of axonal damage distribution.

4.3 Product Applications of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. delivers comprehensive solutions for NfL research and clinical detection through its specialized sub-brands:

• Starter sub-brand (antibodies):
• NfL Recombinant Rabbit mAbs (S0B3280, SDT-635-313; S0B3279, SDT-635-214): Form a high-sensitivity antibody pair with sandwich ELISA sensitivity of 20 pg/ml. They exhibit no cross-reactivity with GFAP, ensuring specific NfL detection in CSF and blood.
• Complementary Tau/pTau antibodies: Enable multi-biomarker analysis for neurodegenerative disease research.
• UA sub-brand (recombinant proteins):
• Human NfL, His tag (S0A9049, E.coli expression; S0B3279, HEK293 expression): High-purity recombinant proteins for assay development, calibration, and quality control.

All products are validated on advanced platforms, comply with EU 98/79/EC, ISO9001, and ISO13485 certifications, and support diverse applications—from basic neuroscience research to clinical diagnostic kit development.

5. Brand Mission of ANT BIO PTE. LTD.

ANT BIO PTE. LTD. is dedicated to empowering global life science research and clinical practice through high-quality, innovative reagents and professional services. As a leading provider of life science solutions, the company offers a comprehensive portfolio including antibodies, recombinant proteins, ELISA kits, and general laboratory reagents, with three specialized sub-brands: Absin (general reagents and kits), Starter (antibodies), and UA (recombinant proteins). Leveraging advanced R&D platforms—including recombinant antibody development (rabbit/mouse monoclonal), protein expression systems (E.coli, CHO, HEK293, Insect Cells), One-Step ELISA, and PTM Pan-Modification Antibody platforms—ANT BIO PTE. LTD. adheres to the principles of "precision, reliability, and customer-centricity." The company strives to deliver cost-effective products and tailored support to researchers, clinicians, and biopharmaceutical partners, accelerating the translation of scientific discoveries into improved patient care and advancing global neuroscience research.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.